Duodopa pump treatment in patients with advanced Parkinson's disease

Danish Medical Bulletin

Volumn 57, Issue 6, 2010, Pages

  Karlsborg, Merete ^a   Korbo, Lise ^a   Regeur, Lisbeth ^a   Glad, Arne ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; LEVODOPA;

AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEMENTIA; DISEASE SEVERITY; DUODENUM; DYSKINESIA; FEMALE; GAIT; HUMAN; HYPERKINESIA; IDIOPATHIC DISEASE; INFUSION PUMP; MALE; PAIN; PARKINSON DISEASE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PERITONITIS; RATING SCALE; VIDEORECORDING; COHORT ANALYSIS; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COHORT STUDIES; FEMALE; HUMANS; INFUSION PUMPS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77954590427     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):2-11.
2. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 1991;41:168-73.
3. Marconi R, Landi A, Valzania F. Subthalamic nucleus stimulation in Parkinson's disease. Neurol Sci 2008;29 Suppl 5:S389-91.
4. Voon V, Kubu C, Krack P et al. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21(Suppl. 14):S305-27.
5. Stocchi F. Use of apomorphine in Parkinson's disease. Neurol Sci 2008;29 Suppl 5: S383-6.
6. DeGaspari D, Siri C, Landi A et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006:77:450-53.
7. Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63.
8. Bredberg E, Nilsson D, Johansson K et al. Intraduodenal infusion of a water-based levodopa dispension for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993;45:117-22.
9. Antonini A, Isaias I, Canesi M et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-months treatment outcome. Mov Disord 2007;22:1145-9.
10. Westin J, Nyholm D, Groth T et al. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. Parkinsonism and related Disorders 2006:12; 509-13.
11. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008;29 Suppl 5: S387-8.
12. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87.
13. Nyholm D, Lewander T, Johansson A et al. Intraduodenal infusion of a gel suspension of levodopa/carbidopa, Duodopa, in advanced Parkinson's disease: safety, tolerability, efficacy and dosage. Mov Disord 2004;19(Suppl.9):S177.
14. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Rel Disord 2007;13:S13-17.
15. Nyholm D, Lewander T, Johansson A et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term Exposure. Clin Neuropharmacol 2008;31:63-73.
16. Chapuis S, Ouchchane L, Metz O et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20:224-30.